Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 18, 2015, Pages 5803-5808

  Ebert, Gregor ^a,b   Allison, Cody ^a,b   Preston, Simon ^a,b   Cooney, James ^a   Toe, Jesse G ^a,b   Stutz, Michael D ^a,b   Ojaimi, Samar ^a,b   Baschuk, Nikola ^c   Nachbur, Ueli ^a,b   Torresi, Joseph ^b   Silke, John ^a,b   Begley, C Glenn ^d   Pellegrini, Marc ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d TetraLogic Pharmaceuticals   (United States)

Author keywords

Birinapant; Cellular inhibitor of apoptosis proteins; Hepatitis B virus; Smac mimetic; TNF

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BIRINAPANT; ENTECAVIR; GT 13072; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN; N [1 CYCLOHEXYL 2 [2 [4 (4 FLUOROBENZOYL) 2 THIAZOLYL] 1 PYRROLIDINYL] 2 OXOETHYL] 2 (METHYLAMINO)PROPANAMIDE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS DNA; DIPEPTIDE; GUANINE; INDOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; DNA VIRUS; DRUG POTENTIATION; FLOW CYTOMETRY; HEPATITIS B; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRAL CLEARANCE; VIRUS GENOME; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C3H MOUSE; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; HEPATITIS B VIRUS; IMMUNOPHENOTYPING; LIVER; METABOLISM; PLASMID; SCANNING ELECTRON MICROSCOPY; VIROLOGY;

ANIMALIA; HEPATITIS B VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DIPEPTIDES; DISEASE MODELS, ANIMAL; DNA, VIRAL; GUANINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATOCYTES; IMMUNOPHENOTYPING; INDOLES; INHIBITOR OF APOPTOSIS PROTEINS; LIVER; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICROSCOPY, ELECTRON, SCANNING; PLASMIDS;

EID: 84928947363     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1502400112     Document Type: Article

References (24)

1. Ebert G, et al. (2015) Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus. Proc Natl Acad Sci USA 112:5797-5802.
2. Yang PL, et al. (2010) Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci USA 107(2):798-802.
3. Lee YH, Bae SC, Song GG (2013) Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 31(1):118-121.
4. Lan JL, et al. (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing antitumour necrosis factor alpha therapy. Ann Rheum Dis 70(10):1719-1725.
5. Silke J (2011) The regulation of TNF signalling: What a tangled web we weave. Curr Opin Immunol 23(5):620-626.
6. Vince JE, et al. (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131(4):682-693.
7. Wang L, Du F, Wang X (2008) TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133(4):693-703.
8. Petersen SL, et al. (2007) Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12(5):445-456.
9. Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR (2013) Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat 137(2):359-371.
10. Carter BZ, et al. (2014) Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst 106(2):djt440.
11. Condon SM, et al. (2014) Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem 57(9):3666-3677.
12. Krepler C, et al. (2013) The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res 19(7):1784-1794.
13. Benetatos CA, et al. (2014) Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther 13(4):867-879.
14. Dougan M, et al. (2010) IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med 207(10):2195-2206.
15. Gentle IE, et al. (2014) Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice. Blood 123(5):659-668.
16. Fan LX, et al. (2013) Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts. J Am Soc Nephrol 24(12):2010-2022.
17. Lin YJ, et al. (2010) Hepatitis B virus core antigen determines viral persistence in a C57BL/6 mouse model. Proc Natl Acad Sci USA 107(20):9340-9345.
18. Huang LR, Wu HL, Chen PJ, Chen DS (2006) An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci USA 103(47):17862-17867.
19. Pérarnau B, et al. (1999) Single H2Kb, H2Db and double H2KbDb knockout mice: Peripheral CD8+ T cell repertoire and anti-lymphocytic choriomeningitis virus cytolytic responses. Eur J Immunol 29(4):1243-1252.
20. Schmidt J, Blum HE, Thimme R (2013) T-cell responses in hepatitis B and C virus infection: Similarities and differences. Emerg Microbe Infect 2:e15.
21. Wilson EB, et al. (2013) Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340(6129):202-207.
22. Teijaro JR, et al. (2013) Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340(6129):207-211.
23. Komarova NL, Barnes E, Klenerman P, Wodarz D (2003) Boosting immunity by antiviral drug therapy: A simple relationship among timing, efficacy, and success. Proc Natl Acad Sci USA 100(4):1855-1860.
24. Bertoletti A, Gehring AJ (2006) The immune response during hepatitis B virus infection. J Gen Virol 87(Pt 6):1439-1449.